Kidney International Reports最新文献

{"title":"Prophylactic and Therapeutic Anticoagulation in Nephrotic Syndrome Using Direct Acting Oral Anticoagulants","authors":"Donal J. Sexton , Adam Bowden","doi":"10.1016/j.ekir.2025.02.021","DOIUrl":"10.1016/j.ekir.2025.02.021","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 991-993"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome” [Kidney International Reports Volume 9, Issue 10, October 2024, Pages 3053-3056]","authors":"David Massicotte-Azarniouch , Daniel J. Crona , Priscilla Karnabi , Bhadran Bose , Patrick H. Nachman , Marc Carrier , Mark Canney , David W. Johnson , Taewoo Lee , Raja Ramachandran , Vivekanand Jha , Nigel S. Key , Vimal K. Derebail","doi":"10.1016/j.ekir.2025.01.043","DOIUrl":"10.1016/j.ekir.2025.01.043","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Page 1301"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bartonella Endocarditis-Associated Glomerulonephritis: A Mimicker of Autoimmunity and Vasculitis","authors":"Nicole K. Andeen ,&nbsp;Vanderlene L. Kung ,&nbsp;Jane K. Nguyen ,&nbsp;Rupali S. Avasare ,&nbsp;Georges N. Nakhoul ,&nbsp;Nabin K. Shrestha ,&nbsp;Jina T. Makadia ,&nbsp;Tricia Jesperson ,&nbsp;Cynthia C. Nast ,&nbsp;Grace (Hae Yoon) Choung ,&nbsp;Leal Herlitz","doi":"10.1016/j.ekir.2025.01.009","DOIUrl":"10.1016/j.ekir.2025.01.009","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Bartonella spp.</em> are highly fastidious gram-negative facultative intracellular bacteria which can cause a culture-negative infective endocarditis (IE) with unique clinicopathologic features.</div></div><div><h3>Methods</h3><div>In this study, we assembled 20 cases of glomerulonephritis (GN) due to <em>Bartonella</em> IE from 3 institutions and compared them with 49 cases of culture-positive IEGN and 30 cases of non-endocarditis infection-related GN (IRGN).</div></div><div><h3>Results</h3><div>IEGN was seen in approximately 0.15% to 0.4% of native renal biopsies, with <em>Bartonella</em> causing 8% to 21% of IEGN. Patients with <em>Bartonella</em> IEGN had preexisting cardiac valve alterations (75%); antineutrophil cytoplasmic autoantibody (ANCA) positivity (67%); hypocomplementemia (75%); antinuclear antibody positivity (53%); cryoglobulinemia (45%); and hematologic manifestations, including B-symptoms (79%), splenomegaly (59%), thrombocytopenia (83%), and pancytopenia (44%). In 75% of the cases, <em>Bartonella</em> endocarditis was not diagnosed until after kidney biopsy. Pathologically, <em>Bartonella</em> IEGN presented as a focally crescentic GN, which was C3 codominant (80%) with strong IgM (65%) and/or C1q (55%), or pauci-immune (10%), with predominantly mesangial deposits and limited exudative features. At a median follow-up time of 15 months, progression to end-stage kidney disease (ESKD) for all-comers with IEGN was associated with higher creatinine levels at diagnosis, presence of nephrotic syndrome, female sex, and C1q staining intensity. Although delayed diagnosis of infection and immunosuppressive therapy for presumed autoimmune disease before kidney biopsy were more common in <em>Bartonella</em> IEGN than in culture-positive IEGN, neither were associated with ESKD.</div></div><div><h3>Conclusion</h3><div>IEGNs share laboratory and biopsy features with autoimmunity, which may obfuscate identification of underlying bacterial infection.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1237-1247"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study","authors":"Caroline Arches ,&nbsp;Arwa Jalal-Eddine ,&nbsp;Dimitri Titeca-Beauport ,&nbsp;Myriam Dao ,&nbsp;Thierry Lobbedez ,&nbsp;Philippe Zaoui ,&nbsp;Christophe Masset ,&nbsp;Dominique Bertrand ,&nbsp;Khalil El Karoui ,&nbsp;Henri Brenier ,&nbsp;Hamza Sakhi ,&nbsp;Bastien Peiffer ,&nbsp;Vincent Audard ,&nbsp;Nizar Joher","doi":"10.1016/j.ekir.2025.01.042","DOIUrl":"10.1016/j.ekir.2025.01.042","url":null,"abstract":"<div><h3>Introduction</h3><div>The optimal management of thromboembolism (TE) in patients with nephrotic syndrome (NS) remains challenging. Until now, anticoagulation therapy for NS consisted of vitamin K antagonists (VKAs) or heparin. Data on direct oral anticoagulant (DOAC) use in NS are limited, and their safety and convenience have been well-demonstrated in other indications.</div></div><div><h3>Methods</h3><div>We conducted a multicenter retrospective study of adult patients with NS treated with therapeutic-dose anticoagulation between 2014 and 2022. We compared the incidences of bleeding and TE events between patients receiving DOAC and those receiving VKAs or heparin (standard-of-care [SOC]). Patients with end-stage kidney disease were excluded.</div></div><div><h3>Results</h3><div>The overall population consisted of 144 patients (median [interquartile range] age of 54 [38–67] years, 34.7% women) with a median albumin level at 1.5 (1.2–1.8) g/dl and a median urinary protein-to-creatinine ratio of 8.8 (5.5–12.3)g/g. Membranous nephropathy was the main NS etiology (45.8%). No significant differences were observed between the DOAC (<em>n</em> = 72) and the SOC (<em>n</em> = 72) groups. The anticoagulant strategy was primary prophylaxis in 79.2% of patients taking DOAC and 83.3% of patients with SOC (<em>P</em> = 0.67). DOAC use was not associated with an increased rate of TE (4.2% vs. 0%, <em>P</em> = 0.25) or bleeding events (6.9% vs. 13.9%, <em>P</em> = 0.28) compared with the SOC group. Univariate analysis identified female sex, age &gt; 75 years, and anticoagulant exposure &gt; 90 days as risk factors for bleeding.</div></div><div><h3>Conclusion</h3><div>This study suggests that DOAC are safer and more effective than conventional anticoagulant strategies for both primary and secondary prophylaxis in patients with NS.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1188-1195"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inside CKD: Cost-Effectiveness of Multinational Screening for CKD","authors":"Navdeep Tangri ,&nbsp;Kook-Hwan Oh ,&nbsp;Jason C.J. Choo ,&nbsp;Michel Jadoul ,&nbsp;Johan Ärnlöv ,&nbsp;Marcelo Costa Batista ,&nbsp;Christian F. Christiansen ,&nbsp;Gil Chernin ,&nbsp;Lise Retat ,&nbsp;Joshua Card-Gowers ,&nbsp;Timothy Coker ,&nbsp;Salvatore Barone ,&nbsp;Stephen Nolan ,&nbsp;Juan Jose Garcia Sanchez","doi":"10.1016/j.ekir.2025.01.020","DOIUrl":"10.1016/j.ekir.2025.01.020","url":null,"abstract":"<div><h3>Introduction</h3><div>Early detection of chronic kidney disease (CKD) could slow its progression; however, most patients in earlier stages remain undiagnosed. Our study objective was to assess the cost-effectiveness of multinational CKD screening strategies from the payer perspective across general and higher-risk populations.</div></div><div><h3>Methods</h3><div>Using the published Inside CKD microsimulation, we projected virtual closed populations to assess CKD screening strategies in 31 countries or regions over a lifetime horizon. We considered people aged ≥ 65 or ≥ 45 years in the general population and in high-risk subgroups (type 2 diabetes [T2D], hypertension, or cardiovascular disease [CVD]). Simulated populations could receive 2 serum creatinine (SCr) tests assessing estimated glomerular filtration rate (eGFR), “2 eGFR only”, or an additional urinary albumin-to-creatinine ratio test (UACR), “2 eGFR and 1 UACR”, versus current practice. Eligible patients received renin-angiotensin system inhibitors (RASi).</div></div><div><h3>Results</h3><div>Screening the general population aged ≥ 45 years for CKD was cost-effective versus current practice in all countries or regions using the “2 eGFR and 1 UACR” strategy, and cost-effective in all but 1 country using the 2 eGFR only strategy. The 2 eGFR and 1 UACR strategy showed consistently higher cost-effectiveness. Screening general populations aged ≥ 45 years increased projected CKD diagnosis rates per 100,000 persons eligible for screening from 459 by current practice to 7475 patients using 2 eGFR only, or 14,392 using 2 eGFR and 1 UACR. Similar trends in cost-effectiveness and diagnosis rates were observed in persons aged ≥ 65 years.</div></div><div><h3>Conclusion</h3><div>CKD screening may be cost-effective in general populations worldwide, including in populations aged ≥ 45 years. Our analysis corroborates global guideline recommendations for simultaneous eGFR and UACR testing if considered in the context of local factors.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1087-1100"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for Patients With a Deceased Donor Kidney Offer in the New Allocation System","authors":"Sumit Mohan ,&nbsp;Miko Yu ,&nbsp;Lindsey M. Maclay ,&nbsp;Joel T. Adler ,&nbsp;Anne M. Huml ,&nbsp;Jesse D. Schold ,&nbsp;S. Ali Husain","doi":"10.1016/j.ekir.2025.01.021","DOIUrl":"10.1016/j.ekir.2025.01.021","url":null,"abstract":"<div><h3>Introduction</h3><div>In the United States (US), disparities in access to kidney transplantation exist for waitlisted candidates with end-stage kidney disease. Meanwhile, changes in kidney allocation policy have been associated with a dramatic increase in the number of organ offers declined before an organ is successfully placed.</div></div><div><h3>Methods</h3><div>We describe transplant and mortality rates for waitlisted candidates from 2015 to 2022 following these allocation changes.</div></div><div><h3>Results</h3><div>Among 249,145 incident waitlisted adults, 180,039 received at least 1 offer and were included in the study. Of these, 37.7% received a deceased donor kidney allograft, 14.7% received a living donor allograft, 7.4% died while on the waiting list, 12.7% were removed, and 27.5% were still waitlisted by the study end period. Overall, candidates’ median number of days to receiving their first offer declined from 20 (7–48) in 2015 to 5 (2–13) in 2022. Candidates who died while on the waiting list received a median of 25 (9–56) offers and candidates who were removed received a median of 22 (8–53) offers during the study period. The total number of offers generated by the match-run algorithm, including those from nonutilized kidneys, increased sharply from 7,911,688 offers in 2015 to 13,682,914 in 2019, and to 29,332,516 in 2022.</div></div><div><h3>Conclusion</h3><div>These findings emphasize the inefficiencies inherent in our current allocation algorithms and the need to rethink how waitlisted patients are prioritized for a given deceased donor organ in order to maximize the probability of appropriate utilization of lifesaving organs .</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1111-1121"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort","authors":"Anne-Laure Sellier-Leclerc ,&nbsp;Melissa Cloarec ,&nbsp;Bertrand Knebelmann ,&nbsp;Lise Allard ,&nbsp;Olivia Boyer ,&nbsp;Sylvie Cloarec ,&nbsp;Claire Dossier ,&nbsp;Moglie Le Quintrec ,&nbsp;François Nobili ,&nbsp;Thomas Stehlé ,&nbsp;Isabelle Vrillon ,&nbsp;Stéphane Burtey ,&nbsp;Emilie Cornec-Le Gall ,&nbsp;Marie Courbebaisse ,&nbsp;Thierry Frouget ,&nbsp;Arnaud Garnier ,&nbsp;Thierry Krummel ,&nbsp;Sandrine Lemoine ,&nbsp;Catherine Monet-Didailler ,&nbsp;Caroline Rousset-Rouvière ,&nbsp;Justine Bacchetta","doi":"10.1016/j.ekir.2024.12.033","DOIUrl":"10.1016/j.ekir.2024.12.033","url":null,"abstract":"<div><h3>Introduction</h3><div>Lumasiran is a drug used in RNA-interference (RNAi) therapy for primary hyperoxaluria type 1 (PH1). Data on its efficacy and safety mainly come from industry-sponsored trials.</div></div><div><h3>Methods</h3><div>For postmarketing follow-up, French authorities requested a quasi-exhaustive retrospective and prospective study over 5 years for patients receiving lumasiran, requiring the inclusion of at least 90% of patients, named as the DAILY-LUMA cohort (NCT06225882). Here, we analyzed data from all patients who were not previously included in the industry-sponsored trials and had received lumasiran for at least 2 years.</div></div><div><h3>Results</h3><div>We included 38 patients, 22 from DAILY-A (i.e., estimated glomerular filtration rate (eGFR) &gt; 45 ml/min per 1.73 m², age ≥ 6 years), 6 from DAILY-B (i.e., eGFR &gt; 45 ml/min per 1.73 m², age &lt; 6 years), and 10 from DAILY-C (i.e., all ages, eGFR &lt; 45 ml/min per 1.73 m², 6 on dialysis). In DAILY-A and DAILY-B, decreased urinary oxalate-to-creatinine (UOx/creat) ratio, stable eGFR, and decrease in both nephrocalcinosis severity and stone numbers were observed, with a progressive tapering of conservative therapies. The decreased proportion of patients with nocturnal hydration and G-tubes overtime likely reflects improved quality of life. With a low number of patients — 2 patients on peritoneal dialysis and 3 patients with infantile oxalosis — the results are less conclusive for DAILY-C; however, in older patients, change in plasma oxalate (POx) levels is similar to previously published data. Tolerance was good with no severe side effects; injection site reactions, abdominal pain, and headaches were the main adverse events.</div></div><div><h3>Conclusion</h3><div>DAILY-LUMA is the largest cohort of patients receiving lumasiran in real life, confirming its safety and efficacy at 2 years.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1020-1036"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Transplantation Improves Survival in Lupus Nephritis With End-Stage Kidney Disease","authors":"Benoît Brilland ,&nbsp;Jean-François Augusto ,&nbsp;Pierre-Antoine Michel ,&nbsp;Noémie Jourde-Chiche ,&nbsp;Cécile Couchoud ,&nbsp;Renal Epidemiology and Information Network (REIN) registry","doi":"10.1016/j.ekir.2025.01.034","DOIUrl":"10.1016/j.ekir.2025.01.034","url":null,"abstract":"<div><h3>Introduction</h3><div>Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) and is associated with high morbidity and mortality rates. Although kidney transplantation (KT) is considered the optimal treatment for end-stage kidney disease (ESKD), its survival benefit, specifically in patients with LN-induced ESKD (LN-ESKD), is not well-established. This study aimed to determine the effects of KT on the survival of a national cohort of patients with LN-ESKD.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed patients with LN-ESKD registered in the French Renal Epidemiology and Information Network (REIN) registry, who were waitlisted for KT between 2002 and 2022. KT was treated as a time-dependent variable to avoid an immortal time bias. The primary outcome was all-cause mortality, which was assessed using Kaplan-Meier analysis and adjusted Cox proportional hazards models.</div></div><div><h3>Results</h3><div>Of the 882 patients with LN-ESKD, 636 (72%) were waitlisted for KT, and 470 (74%) received a transplant. After a median follow-up of 80 months, KT was associated with a 60% reduction in the risk of death compared with remaining on dialysis (hazard ratio [HR]: 0.40, 95% confidence interval [CI]: 0.240–0.67, <em>P</em> &lt; 0.001), with consistent benefits across subgroups. Patient survival at 10 years was 83% for transplant recipients and 60% for nontransplant recipients (<em>P</em> &lt; 0.001). Sensitivity analyses, after excluding recipients of living donors and patients who were inactivated from the waitlist, supported these findings. Two years after the onset of ESKD, 38% of the waitlisted patients under went transplantation. The probability of graft failure was 23% at 10 years posttransplant.</div></div><div><h3>Conclusion</h3><div>Compared with patients who remain on dialysis, KT is associated with improved survival in patients with LN-ESKD. Early evaluation of transplant eligibility and timely referral to transplant centers are crucial for optimizing outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1163-1174"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan","authors":"Kiyotaka Uchiyama ,&nbsp;Daisuke Kamano ,&nbsp;Tomoki Nagasaka ,&nbsp;Eriko Yoshida Hama ,&nbsp;Ryoichi Shirai ,&nbsp;Rena Sumura ,&nbsp;Ei Kusahana ,&nbsp;Akane Yanai ,&nbsp;Takashin Nakayama ,&nbsp;Takahide Kimura ,&nbsp;Rina Takahashi ,&nbsp;Takahiro Kasai ,&nbsp;Takaya Tajima ,&nbsp;Koji Hosoya ,&nbsp;Tatsuhiko Azegami ,&nbsp;Shintaro Yamaguchi ,&nbsp;Jun Yoshino ,&nbsp;Jun Ito ,&nbsp;Matsuhiko Hayashi ,&nbsp;Takeshi Kanda ,&nbsp;Kaori Hayashi","doi":"10.1016/j.ekir.2025.01.023","DOIUrl":"10.1016/j.ekir.2025.01.023","url":null,"abstract":"<div><h3>Introduction</h3><div>Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established. We conducted an open-label, randomized controlled crossover trial to evaluate the additive effects of dapagliflozin in patients with ADPKD receiving tolvaptan.</div></div><div><h3>Methods</h3><div>A total of 27 patients were randomly counterbalanced to receive dapagliflozin 10 mg or usual care without dapagliflozin for 6 months. The primary endpoint was the slope of the estimated glomerular filtration rate (eGFR) determined by linear regression from 1 to 6 months, and the secondary endpoints included changes in total kidney volume (TKV). eGFR was calculated based on creatinine levels (eGFR_cr), cystatin C levels (eGFR_cys), and the mean of eGFR_cr and eGFR_cys (eGFR_cr-cys).</div></div><div><h3>Results</h3><div>There were significant attenuations in the eGFR_cr-cys and eGFR_cys slopes during the dapagliflozin trial compared with the one without dapagliflozin (2.57 ± 7.88 vs. −5.65 ± 9.57 ml/min per 1.73 m² per year, <em>P</em> = 0.002; 3.91 ± 11.40 vs. −8.43 ± 13.44 ml/min per 1.73 m² per year, <em>P</em> = 0.003, respectively). Meanwhile, the eGFR_cr slope was potentially moderate during the trial with dapagliflozin (1.03 ± 10.78 vs. −3.66 ± 8.88 ml/min per 1.73 m² per year, <em>P</em> = 0.06). The 6-month change in TKV was significantly attenuated during the trial with dapagliflozin compared with the one without dapagliflozin (−0.44 ± 4.91% vs. 5.04 ± 8.09%, <em>P</em> = 0.01).</div></div><div><h3>Conclusion</h3><div>In patients with ADPKD treated with tolvaptan, dapagliflozin may have an additive effect in slowing ADPKD progression.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1063-1075"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Provider Attitudes Toward Patient-Facing Kidney Organ Offer Reporting","authors":"Syed Ali Husain ,&nbsp;Jordan A. Rubenstein ,&nbsp;Seshma Ramsawak ,&nbsp;Anne M. Huml ,&nbsp;Miko E. Yu ,&nbsp;Lindsey M. Maclay ,&nbsp;Jesse D. Schold ,&nbsp;Sumit Mohan","doi":"10.1016/j.ekir.2025.01.013","DOIUrl":"10.1016/j.ekir.2025.01.013","url":null,"abstract":"<div><h3>Introduction</h3><div>In the United States (US), deceased donor kidney offers are most commonly declined by transplant centers on behalf of waitlisted candidates, without notifying them. We sought to understand patient and provider attitudes toward patient-facing organ offer reporting.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional survey of patients, nephrologists, and nephrology social workers on the National Kidney Foundation mailing list and the medical and surgical directors of US kidney transplant programs.</div></div><div><h3>Results</h3><div>Among 755 patient respondents, 64% wanted to receive organ offer reports. Patients who wanted organ offer information were younger, more likely to be of a non-White race, and more likely to be on dialysis or on the waiting list. Of the patients, 87% reported that centers should be required to tell candidates about the offers they receive, and 62% reported that candidates should be informed after every offer. Among the 107 nephrology respondents, 73% reported that candidates should be provided with organ offer information and 88% reported that they would want to receive a copy of their patients’ offer reports. Among 26 transplant program director respondents, 77% reported that candidates should not be notified of offers declined on their behalf. If organ offer reports were required, most program director respondents believed that they should include the reasons offers were declined and should not include offers for kidneys that were ultimately discarded.</div></div><div><h3>Conclusions</h3><div>Most patients and nephrology providers, but only a minority of transplant program directors, supported the sharing of patient-facing information about individual deceased donor kidney offers that were declined on candidates’ behalf.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1122-1130"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}